Maintenance therapy for extensive stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests if a combination of an immunotherapy drug (PD-L1 inhibitor) and a targeted therapy pill (apatinib) can help keep extensive stage small cell lung cancer from growing after initial treatment. It is for people whose cancer was controlled with first-line chemo-immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have extensive stage small cell lung cancer (cancer that has spread far from the lung).
- You must have already completed your first round of treatment with a PD-L1 immunotherapy drug plus chemotherapy, and the cancer stopped growing or got smaller.
- You need to be between 18 and 75 years old and in reasonably good health (able to take care of yourself and do light activities).
- Your blood counts, liver, and kidney function must be within certain limits (your doctor will check this).
- You cannot have certain other medical conditions, like an active autoimmune disease, serious heart problems, or active infections like hepatitis B or C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two targeted/immune drugs with standard chemotherapy as a first treatment for extensive small cell lung cancer. It aims to see if this approach is safe and effective for people who have not had prior treatment for this cancer.
This trial tests a combination of two drugs, liposomal irinotecan and apatinib, for people with extensive-stage small cell lung cancer (ES-SCLC) that has progressed after first or second line treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
This trial is testing whether a maintenance therapy using anlotinib (a drug that blocks blood vessel growth) combined with immunotherapy can help keep extensive-stage small cell lung cancer from progressing after initial chemoimmunotherapy. It aims to see if this reduces the chance of the cancer coming back and improves survival.
This trial tests a combination of two drugs — sintilimab (an immunotherapy) and anlotinib (a targeted therapy) — for people with small cell lung cancer that has worsened after previous immunotherapy. The goal is to see if this combination can help control the cancer when standard treatments have stopped working.
This study tests a new combination treatment for extensive-stage small cell lung cancer. You would receive an immunotherapy drug (adebrelimab) together with chemotherapy and a very low dose of chest radiation, to see if this helps control the cancer better.
This trial studies how well pembrolizumab, plinabulin, and etoposide plus platinum work as first treatment for extensive-stage small cell lung cancer. It may help some people by boosting the immune response while also attacking cancer with standard chemotherapy.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.